Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash & Equivalents (2016 - 2026)

Wave Life Sciences filings provide 13 years of Cash & Equivalents readings, the most recent being $544.6 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 124.02% to $544.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $544.6 million, a 124.02% increase, with the full-year FY2025 number at $602.1 million, up 99.31% from a year prior.
  • Cash & Equivalents hit $544.6 million in Q1 2026 for Wave Life Sciences, down from $602.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $602.1 million in Q4 2025 to a low of $61.7 million in Q1 2022.
  • Median Cash & Equivalents over the past 5 years was $196.2 million (2025), compared with a mean of $227.0 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 58.45% in 2022 and later soared 236.33% in 2023.
  • Wave Life Sciences' Cash & Equivalents stood at $88.5 million in 2022, then skyrocketed by 126.39% to $200.4 million in 2023, then surged by 50.77% to $302.1 million in 2024, then soared by 99.31% to $602.1 million in 2025, then dropped by 9.55% to $544.6 million in 2026.
  • The last three reported values for Cash & Equivalents were $544.6 million (Q1 2026), $602.1 million (Q4 2025), and $196.2 million (Q3 2025) per Business Quant data.